Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Wins Second Service Contract with USC; Sets Date for 04 Annual Meeting to Vote on Solexa Merger

The date of Lynx's shareholder meeting is March 1, not March 21.

NEW YORK, Jan. 31 (GenomeWeb News) - Researchers at the University of Southern California will continue to use Lynx's gene-expression technology to study oyster larval development after winning a new grant from the National Science Foundation, Lynx said today.


Under the new agreement with USC, Lynx will be paid for performing genome-wide transcriptome sequencing services on oyster samples, using its massive parallel signature sequencing technology.


Separately, Lynx said it will hold its 2004 annual meeting of stockholders on March 1, where shareholders will vote on the proposed merger with Solexa.


Lynx also said it will have a hearing before a Nasdaq listing qualifications panel on Feb. 9 to review Nasdaq's decision to delist the company from the Nasdaq SmallCap Market after Lynx failed to hold an annual stockholder meeting by Dec. 31, 2004.


"We believe that following the upcoming stockholders' meeting, Lynx will again be in full compliance with Nasdaq listing requirements," acting CEO Mary Schramke said in a statement today.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.